Is Neurocrine Biosciences, Inc. (NBIX) a Buy, Sell, or Hold?
NASDAQ : NBIX
Neurocrine Biosciences, Inc. — Stock Grades
$166.8 USD
-$18.7 (-10.08%)
- Volume
- 4.58M
- Average Volume
- 1.29M
- Market Capitalization
- $16.77B
- P/E Ratio
- 23.66
- Dividend Yield
- 0.00%
- Price Target
- $200.00
- Year High
- $186.12
- Year Low
- $122.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.87
NBIX Stock Grades
| Date | Grading Company | Previous Grade | New Grade | Action |
|---|---|---|---|---|
| 2026-07-31 | Guggenheim | Buy | Buy | Maintain |
| 2026-07-31 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2026-07-31 | Stifel | Buy | Buy | Maintain |
| 2026-07-31 | Citigroup | Buy | Buy | Maintain |
| 2026-07-31 | Needham | Buy | Buy | Maintain |
| 2026-07-31 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-07-31 | Morgan Stanley | Equal Weight | Equal Weight | Maintain |
| 2026-07-31 | TD Cowen | Buy | Buy | Maintain |
| 2026-07-31 | Piper Sandler | Overweight | Overweight | Maintain |
| 2026-07-21 | Guggenheim | Buy | Buy | Maintain |
| 2026-07-17 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-07-13 | BMO Capital | Market Perform | Market Perform | Maintain |
| 2026-07-13 | Truist Securities | Buy | Buy | Maintain |
| 2026-07-07 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-05-29 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-05-08 | JP Morgan | Overweight | Overweight | Maintain |
| 2026-05-07 | Truist Securities | Buy | Buy | Maintain |
| 2026-05-06 | Citigroup | Buy | Buy | Maintain |
| 2026-05-06 | Morgan Stanley | Equal Weight | Equal Weight | Maintain |
| 2026-05-06 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-05-06 | Piper Sandler | Overweight | Overweight | Maintain |
| 2026-05-06 | Guggenheim | Buy | Buy | Maintain |
| 2026-05-06 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-22 | Leerink Partners | Outperform | Outperform | Maintain |
| 2026-04-10 | Morgan Stanley | Equal Weight | Equal Weight | Maintain |
| 2026-04-07 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-04-07 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-07 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-07 | Citigroup | Buy | Buy | Maintain |
| 2026-04-06 | Needham | Buy | Buy | Maintain |
| 2026-03-12 | JP Morgan | Overweight | Overweight | Maintain |
| 2026-02-17 | JP Morgan | Overweight | Overweight | Maintain |
| 2026-02-17 | Truist Securities | Buy | Buy | Maintain |
| 2026-02-13 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-02-12 | BMO Capital | Market Perform | Market Perform | Maintain |
| 2026-02-12 | Wedbush | Outperform | Outperform | Maintain |
| 2026-02-12 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-02-12 | Needham | Buy | Buy | Maintain |
| 2026-02-12 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-02-12 | Citigroup | Buy | Buy | Maintain |
| 2026-01-23 | UBS | Buy | Buy | Maintain |
| 2026-01-12 | JP Morgan | Overweight | Overweight | Maintain |
| 2026-01-08 | Truist Securities | Buy | Buy | Maintain |
| 2026-01-08 | Morgan Stanley | Overweight | Equal Weight | Downgrade |